Pharmaceutical composition containing ghrp-6 to prevent and eliminate fibrosis and other pathological deposits in tissues

Abstract

The present invention is related to the use of secretagogue peptides repeatedly administered as part of a pharmaceutical composition that prevent and eradicate the deposition of pathological fibrotic material in parenchymal tissues of internal organs like the liver, lungs, esophagus, small intestine, kidneys, blood vessels, joints, and other systemic forms of cutaneous fibrosis of any etiopathogenesis. Additionally, these peptides prevent and eradicate deposition of amiloid and hyaline materials in any of their correspondent chemical forms and tissue manifestations in the brain, cerebellum, blood vessels, liver, intestines, kidneys, spleen, pancreas, joints and the skin, among others. By this way, cellular, tissular and organ dysfunctions generated by these depositions are corrected. The peptides of the present invention are infiltrated or topically applied, contributing to prevent and eradicate keloids and hypertrophic scars in the skin, derived as sequelae of burns and other cutaneous trauma.

1 . A pharmaceutical composition characterized by containing GHRP-6 and capable of preventing, controlling and eliminating the pathological deposits of fibrotic material and the excess of extracellular matrix from internal organs and the skin of the recipient organism. 
   
   
       2 . A composition according to  claim 1 , wherein said composition eliminates the intracellular and extracellular deposits of hyaline and amiloid materials, granular forms of eosinophilic and/or osmophilic material from internal and external organs and the vascular network. 
   
   
       3 . A composition according to  claim 1 , wherein said composition restores the normal functionality of any internal or external organ or tissue affected by excessive deposits of fibrotic, amiloid, osmophilic, eosinophilic or hyaline material. 
   
   
       4 . A composition according to  claim 1 , wherein said composition is administered to animals or patients. 
   
   
       5 . A composition according to  claim 1 , wherein said composition is to be administered to animals or patients by parenteral route, including intravenous, intramuscular, subcutaneous, intraperitoneal, intrathecal; or locally infiltrated into the skin, on mucosa, epithelia or organs, or more precisely intralesionally. 
   
   
       6 . A composition according to  claim 1 , wherein said composition is to be administered to animals or patients by intra-rectal route. 
   
   
       7 . A composition according to  claim 1 , wherein said composition is to be administered to animals or patients by topical route as a liquid, compress, or solid or semi-solid formulations. 
   
   
       8 . A composition according to  claim 1 , wherein said composition is to be administered to animals or patients by any of the routes selected from the group consisting of intravenous intramuscular subcutaneous intraperitoneal intrathecal intra-rectally: or locally infiltrated into the skin, on mucosa, epithelia or organs or more precisely intralesionally, able to eliminate the deposits of fibrotic material and the excess of extracellular matrix in any hepatic etiopathogenesis, like viral hepatitis sequelae, alcoholism, intoxications, autoimmune or idiopathic, in general. 
   
   
       9 . A composition according to  claim 1 , wherein said composition is to be administered to animals or patients by any of the routes selected from the group consisting of intravenous intramuscular subcutaneous intraperitoneal intrathecal intra-rectally; or locally infiltrated into the skin, on mucosa, epithelia or organs or more precisely intralesionally, able to eliminate the deposits of fibrotic material and the excess of extracellular matrix of toxic, professional, drug-related, radioactive, autoimmune, asthmatic sequelae, allergic or idiopathic origin, in general, in organs like lungs. 
   
   
       10 . A composition according to  claim 1 , wherein said composition is to be administered to animals or patients by any of the routes selected from the group consisting of intravenous intramuscular subcutaneous intraperitoneal intrathecal intra-rectally: or locally infiltrated into the skin, on mucosa, epithelia or organs or more precisely intralesionally, able to eliminate the deposits of fibrotic, fibro-hyaline or amiloid material and the excess of extracellular matrix in organs like kidneys, being the nephrosclerosis and/or tubulosclerosis of diabetic, toxic, professional, drug-related, autoimmune or idiopathic origin in general, or sequelae of repeated infections. 
   
   
       11 . A composition according to  claim 1 , wherein said composition is to be administered to animals or patients by any of the routes selected from the group consisting of intravenous intramuscular subcutaneous intraperitoneal intrathecal, intra-rectally; or locally infiltrated into the skin, on mucosa, epithelia or organs, or more precisely intralesionally, able to eliminate the deposits of fibrotic, fibro-hyaline or amiloid material and the excess of extracellular matrix of autoimmune or idiopathic origin in general in the skin. 
   
   
       12 . A composition according to  claim 1 , wherein said composition is to be administered to animals or patients by any of the routes selected from the group consisting of intravenous, intramuscular, subcutaneous, intraperitoneal, intrathecal, intra-rectally; or locally infiltrated into the skin, on mucosa, epithelia or organs, or more precisely intralesionally, as a liquid, compress or solid or semi-solid formulation, able to eliminate the deposits of fibrotic, fibro-hyaline or amiloid material and the excess of extracellular matrix from skin, more precisely keloids, hypertrophic scars or other forms of exuberant scars. 
   
   
       13 . A composition according to  claim 1 , wherein said composition is to be administered to animals or patients by any of the routes selected from the group consisting of intravenous, intramuscular, subcutaneous, intraperitoneal, intrathecal, intra-rectally; or locally infiltrated into the skin, on mucosa, epithelia or organs, or more precisely intralesionally, as a liquid, compress or solid or semi-solid formulation, able to correct the aesthetic appearance of skin after reconstructive, aesthetic or similar surgery. 
   
   
       14 . The use of the GHRP-6 peptide according to  claim 1  for manufacturing a pharmaceutical composition to be administered to animals or patients by any of the routes selected from the group consisting of intravenous intramuscular subcutaneous, intraperitoneal, intrathecal, intra-rectally; or locally infiltrated into the skin, on mucosa, epithelia or organs, or more precisely intralesionally, as a liquid, compress or solid or semi-solid formulation, in a manner to be able to eliminate the deposits of fibrotic, fibro-hyaline or amiloid material and the excess of extracellular matrix from skin, more precisely fibrotic sequelae of any form of acne. 
   
   
       15 . A composition according to  claim 1 , wherein said composition is to be administered to animals or patients by any of the routes selected from the group consisting of intravenous, intramuscular, subcutaneous, intraperitoneal, intrathecal, intra-rectally; or locally infiltrated into the skin, on mucosa, epithelia or organs, or more precisely intralesionally, able to eliminate the deposits of fibrotic, fibro-hyaline or amiloid material and the excess of extracellular matrix from the pancreas and the digestive tube from the esophagus to the rectum. 
   
   
       16 . A composition according to  claim 1 , wherein said composition is to be administered to animals or patients by any of the routes selected from the group consisting of intravenous, intramuscular, subcutaneous, intraperitoneal, intrathecal, intra-rectally; or locally infiltrated into the skin, on mucosa, epithelia or organs, or more precisely intralesionally, to eliminate the deposits of fibrotic, fibro-hyaline or amiloid material and the excess of extracellular matrix in the vascular network. 
   
   
       17 . A composition according to  claim 1 , wherein said composition is to be administered to animals or patients by any of the routes selected from the group consisting of intravenous intramuscular subcutaneous intraperitoneal intrathecal, intra-rectally; or locally infiltrated into the skin, on mucosa, epithelia or organs, or more precisely intralesionally, to eliminate the deposits of fibrotic or amiloid, and/or osmophilic or eosinophilic material in the brain and brain cells. 
   
   
       18 . A composition according to  claim 1 , wherein said composition is to be administered to animals or patients by any of the routes selected from the group consisting of intravenous intramuscular subcutaneous intraperitoneal intrathecal, intra-rectally; or locally infiltrated into the skin, on mucosa, epithelia or organs, or more precisely intralesionally, able to reduce and/or eliminate the deposition of amiloid and/or hyaline, and/or granular forms of eosinophilic and/or osmophilic material in the vessel network of the body, including the central nervous system and the meninges. 
   
   
       19 . A composition according to  claim 1 , wherein said composition is to be administered to animals or patients by any of the routes selected from the group consisting of intravenous, intramuscular, subcutaneous, intraperitoneal, intrathecal, intra-rectally; or locally infiltrated into the skin, on mucosa, epithelia or organs, or more precisely intralesionally, able to reduce and/or prevent the deposition of fibrotic, amiloid and/or hyaline, and/or granular forms of eosinophilic and/or osmophilic material in the walls of blood vessels in general. 
   
   
       20 . A composition according to  claim 1 , wherein said composition is to be administered to animals or patients by any of the routes selected from the group consisting of intravenous intramuscular subcutaneous intraperitoneal intrathecal intra-rectally; or locally infiltrated into the skin, on mucosa, epithelia or organs or more precisely intralesionally, able to eliminate the deposits of fibrotic, amiloid and/or hyaline, and/or granular forms of eosinophilic or osmophilic material from cranial, extra-cranial, sensitive, motor or mixed nerves and/or those from the neuro-vegetative system. 
   
   
       21 . A composition according to  claim 1 , wherein said composition is to be administered to animals or patients by any of the routes selected from the group consisting of intravenous intramuscular subcutaneous intraperitoneal, intrathecal intra-rectally; or locally infiltrated into the skin, on mucosa, epithelia or organs or more precisely intralesionally, able to reduce and/or prevent the deposition of fibrotic, amiloid and/or hyaline, and/or granular forms of eosinophilic and/or osmophilic material in the walls of blood vessels in general. 
   
   
       22 . A composition according to  claim 1  characterized by containing GHRP-6 or GHRP-2 or Ghrelin or Hexarelin, and able to stop and control the excessive lipid peroxidation and oxidative stress processes in cells, tissues and systemic organs, to be administered to animals or patients by any of the routes selected from the group consisting of intravenous, intramuscular subcutaneous, intraperitoneal, intrathecal intra-rectally; or locally infiltrated into the skin, on mucosa, epithelia or organs or more precisely intralesionally. 
   
   
       23 . A composition according to  claim 22 , characterized by being able to stop and control the excessive lipid peroxidation and oxidative stress processes; particularly in the central nervous system and peripheral nerves, to be administered to animals or patients by any of the routes selected from the group consisting of intravenous intramuscular subcutaneous intraperitoneal intrathecal intra-rectally; or locally infiltrated into the skin, on mucosa, epithelia or organs or more precisely intralesionally. 
   
   
       24 . The use of peptides GHRP-6 or GHRP-2 or Ghrelin or Hexarelin in a pharmaceutical composition useful to stop and control the process of brain aging and deterioration of brain functions because of excessive lipid peroxidation and oxidative stress processes, or damage in the brain vascular system, to be administered to animals or patients by any of the routes selected from the group consisting of intravenous intramuscular subcutaneous intraperitoneal intrathecal intra-rectally; or locally infiltrated into the skin, on mucosa, epithelia or organs or more precisely intralesionally. 
   
   
       25 . The use of peptides GHRP-6 or GHRP-2 or Ghrelin or Hexarelin according to  claim 1  for manufacturing a pharmaceutical composition useful for stopping and controlling the process of brain aging and deterioration of brain functions because of excessive lipid peroxidation and oxidative stress processes or damage in the brain vascular system, to be administered to animals or patients by any of the routes selected from the group consisting of intravenous intramuscular subcutaneous intraperitoneal intrathecal intra-rectally; or locally infiltrated into the skin, on mucosa, epithelia or organs or more precisely intralesionally. 
   
   
       26 . The use of peptides GHRP-6 or GHRP-2 or Ghrelin or Hexarelin according to  claim 1  for manufacturing a pharmaceutical composition useful for stopping and controlling the deposition process of fibrotic, amiloid and/or hyaline, and/or granular forms of eosinophilic and/or osmophilic material in cells or the tissue extracellular space of the central and peripheral nervous systems, and to be administered to animals or patients by any of the routes selected from the group consisting of intravenous, intramuscular, subcutaneous, intraperitoneal, intrathecal, intra-rectally; or locally infiltrated into the skin, on mucosa, epithelia or organs or more precisely intralesionally.